Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease - Wikidata - awgldk - TriplyDB

Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease

Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease

http://www.wikidata.org/entity/Q34742583

about

HSV-2: in pursuit of a vaccine Recent advances in vaccine development for herpes simplex virus types I and II Current status and prospects for development of an HSV vaccine Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine.Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen.Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.Comparison of the host immune response to herpes simplex virus 1 (HSV-1) and HSV-2 at two different mucosal sites.The challenge of developing a herpes simplex virus 2 vaccine.The immunologic basis for severe neonatal herpes disease and potential strategies for therapeutic intervention.Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial.Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?Nucleic acid vaccination strategies against infectious diseases.Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Rese Evaluation of recombinant adenovirus vaccines based on glycoprotein D and truncated UL25 against herpes simplex virus type 2 in mice.Herpes simplex virus genital infections: current concepts.Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.

P2860

Q22306291-1E28C12F-BA62-47CA-A923-88D056C12E5E Q26859623-C23D8176-81FC-4E36-B539-FA4C056C7E19 Q33931016-6DB150BA-BF91-49E3-BECA-C093E89FB728 Q34057952-404794C6-8894-42B5-944A-51A0DA6120C3 Q35058245-E96104C4-7820-4F3B-93E1-B58981344DAE Q35849244-4B0FBB89-3385-41FC-9BE6-6123D2CC8677 Q35867958-E6690BBF-2C8A-4E08-99C4-ED6C79FFB03C Q36155593-8877DF6D-8E41-4A71-A46F-75A88E2BB898 Q36671106-F266BB7E-B885-40CF-80D3-DEE54720F5E2 Q36765590-0EDBCCC3-B89C-455B-B349-689B4AD63A22 Q36824210-735B4A77-D765-43F8-B41B-7E86E04A0F6C Q37125722-B3E7F39E-68DF-4361-A490-2D414BB4B5FF Q37514753-F42A16C0-1B53-4F48-8233-F68439710816 Q38212516-47C3B7FE-7265-4D01-8C0A-F8C1DB38047A Q38586079-2869C25A-863A-45BD-BC6E-A782D9FC9938 Q38947443-E9BFCB6E-9960-41EA-9367-0300DB854F97 Q40257387-ADC3036C-EDA7-47F8-934B-2BD91ABC1CEC Q45363913-6597946A-81DE-424B-84C4-6CB3F1C4491F Q55406946-5327F0BC-8B29-415F-8560-0FF3D6077DFB

P2860

Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease

http://www.wikidata.org/entity/Q34742583

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Immunization with herpes simpl ...... te and recurrent HSV-2 disease

@ast

Immunization with herpes simpl ...... te and recurrent HSV-2 disease

@en

Immunization with herpes simplex virus 2

@nl

type

label

Immunization with herpes simpl ...... te and recurrent HSV-2 disease

@ast

Immunization with herpes simpl ...... te and recurrent HSV-2 disease

@en

Immunization with herpes simplex virus 2

@nl

prefLabel

Immunization with herpes simpl ...... te and recurrent HSV-2 disease

@ast

Immunization with herpes simpl ...... te and recurrent HSV-2 disease

@en

Immunization with herpes simplex virus 2

@nl

P1433

Q34742583-E3E1E6B4-F4EA-4ECE-A2DD-0B319B14696E

P1476

Q34742583-9ED41A2D-A606-4CD8-84E8-AE89F4A4E00E

P2093

Q34742583-4FABF070-39E5-4DA1-9F00-3E6FC23A374C

Q34742583-7A7F3640-C373-48EB-964A-FA8EDC0D17DD

Q34742583-C5C022AB-CBDA-481B-90A8-25A10C92DEBD

P2860

Q34742583-024E300F-26EF-4A01-ADA3-6E15C261127E

Q34742583-043EB92A-6F92-4D75-A121-5BBC78B022E8

Q34742583-07DBE448-0A8A-44E2-B439-74382536321C

Q34742583-0CAEA3CC-CEDE-4EDD-9204-09DB7CEB5C90

Q34742583-0E227313-AFD9-47F2-9402-97D19148DDBB

Q34742583-0EC67C4B-A93E-4B81-B301-17B1DF58BACC

Q34742583-140A006D-D2E5-44DE-BFFC-E426036B1CA3

Q34742583-140B4811-9E9E-4C10-89A0-94652F0BC168

Q34742583-18B776B1-77F4-40CA-8153-E45981265999

Q34742583-1BF05001-2DC0-4EF8-9E07-5B10B846572F

P304

Q34742583-C6D4AA47-8860-4AC2-B9F9-DE9BC76B72D4

P31

Q34742583-49BCEDCE-5B3A-45CE-BF74-72E0993DD8CE

P356

Q34742583-AB3ADA4C-429E-4716-9F3A-828C0E523A81

P407

Q34742583-961BD293-CB3F-4ADE-BE91-E26322BD3104

P433

Q34742583-0946F874-F9EB-4EF0-A48F-638D6545E0BE

P478

Q34742583-7446D200-A68E-4A3D-8B52-5F27F0345B0D

P50

Q34742583-0FAC7487-933E-4FE8-AD67-619D31A24DD6

P577

Q34742583-B829B386-1576-4D2E-8785-AA83B564A931

P698

Q34742583-EB785ABA-CC70-4F79-872B-A173135F5D8B

P921

Q34742583-A0D87D62-76A0-450A-B13D-A9EFA7ED349A

P932

Q34742583-E8FC2FBA-E555-4C30-94CD-689F9A2A0E6E

P356

P1433

Journal of Virology

P1476

Immunization with herpes simpl ...... te and recurrent HSV-2 disease

@en

P2093

Christopher S Morello

http://www.w3.org/2001/XMLSchema#string

Kimberly A Kraynyak

http://www.w3.org/2001/XMLSchema#string

Michael S Levinson

http://www.w3.org/2001/XMLSchema#string

P2860

Herpes Simplex: Insights on Pathogenesis and Possible Vaccines

Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47

Genome-wide analysis reveals a highly diverse CD8 T cell response to murine cytomegalovirus.

Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge

Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines.

Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes.

The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks.

Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.

The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs

Recent progress in herpes simplex virus immunobiology and vaccine research

P304

3461-3472

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02521-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

Deborah H. Spector

P577

2011-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21270160

http://www.w3.org/2001/XMLSchema#string

P921

P932

3067869

http://www.w3.org/2001/XMLSchema#string